Open access
Sep 2026
Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study
The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy, and Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice.
Wid M. Alyamani, Attiah Khobrani, Fawaz O. Alenazy et al.
· Frontiers in Medicine · 0 citations